gamma-hydroxyphenylbutazone: metabolite of phenylbutazone; RN given refers to cpd with unspecified isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 120741 |
| CHEMBL ID | 3544829 |
| SCHEMBL ID | 11196711 |
| MeSH ID | M0051625 |
| Synonym |
|---|
| brn 0309214 |
| 4-(3-hydroxybutyl)-1,2-diphenyl-3,5-pyrazolidinedione |
| 3,5-pyrazolidinedione, 4-(3-hydroxybutyl)-1,2-diphenyl- |
| 3,5-pyrazolidinedione, 1,2-diphenyl-4-(3-hydroxybutyl)- |
| g 28231 |
| gamma-hydroxyphenylbutazone |
| 1,2-diphenyl-3,5-dioxo-4-(3-hydroxybutyl)pyrazolidine |
| 568-76-3 |
| 4-(3-hydroxybutyl)-1,2-diphenylpyrazolidine-3,5-dione |
| |a-hydroxy phenylbutazone |
| FT-0669535 |
| 4-25-00-00265 (beilstein handbook reference) |
| SCHEMBL11196711 |
| CHEMBL3544829 |
| gamma-hydroxy phenylbutazone |
| DTXSID50972248 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Following intravenous injection plasma disposition was described by a three compartment open model with mean elimination half-life (t1/2 beta) and clearance (ClB) values of 35." | ( Pharmacokinetics, metabolism and excretion of phenylbutazone in cattle following intravenous, intramuscular and oral administration. Ayliffe, T; Lees, P; Maitho, TE; Taylor, JB, 1988) | 0.27 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "4 mg/kg bodyweight) of phenylbutazone was administered intravenously and orally to six Welsh mountain ponies to provide data on the pharmacokinetics and bioavailability of the drug." | ( Pharmacokinetics of phenylbutazone in two age groups of ponies: a preliminary study. Lees, P; Maitho, TE; Taylor, JB, 1985) | 0.27 |
| " bioavailability of phenylbutazone was calculated to be 91." | ( The intramuscular bioavailability of a phenylbutazone preparation in the horse. Debackere, M; Delbeke, FT; Landuyt, J, 1993) | 0.29 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Somewhat longer t1/2 beta values were obtained after oral and intramuscular dosing and these may have resulted from sequestration within and slow absorption from the gastrointestinal tract and continual uptake from intramuscular sites following precipitation as a depot." | ( Pharmacokinetics, metabolism and excretion of phenylbutazone in cattle following intravenous, intramuscular and oral administration. Ayliffe, T; Lees, P; Maitho, TE; Taylor, JB, 1988) | 0.27 |
| " Recovery of PBZ and its metabolites from urine was significantly reduced in the first 24 h after oral dosing when the horses had free access to hay, probably as a result of markedly delayed absorption, but this did not occur in animals deprived of food for a few hours before and after dosing." | ( Metabolism, excretion, pharmacokinetics and tissue residues of phenylbutazone in the horse. Higgins, AJ; Lees, P; Maitho, TE; Millar, JD; Taylor, JB, 1987) | 0.27 |
| " Considerable individual variation was observed both in timing and magnitude of the plasma drug responses between horses, but 24 h after dosing a clear dose response relation was recorded." | ( Pharmacokinetics of phenylbutazone and its metabolites in the horse. Gerring, EL; Lees, P; Taylor, JB, 1981) | 0.26 |
| " dosing the plasma disposition was best described by a two-compartment open model." | ( The intramuscular bioavailability of a phenylbutazone preparation in the horse. Debackere, M; Delbeke, FT; Landuyt, J, 1993) | 0.29 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (81.82) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.81) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||